Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jul 31;25(11):2230–2236. doi: 10.1093/annonc/mdu367

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PMC Copyright notice

Figure 1. — Kaplan–Meier survival plots by KRAS-variant status (variant TG/GG versus non-variant TT). (A) Progression-free survival from HN0501 (phase II trial of docetaxel + bortezomib in R/M HNSCC patients); (B) overall survival from HN0501; (C) progression-free survival from E5397 (randomized phase III trial of cisplatin + placebo versus cisplatin + cetuximab in R/M HNSCC patients); (D) overall survival from E5397; (E) progression-free survival by KRAS-variant status (variant TG/GG versus non-variant TT) and E5397 treatment arms (cisplatin + placebo versus cisplatin + cetuximab); and (F) overall survival by KRAS-variant status (variant TG/GG versus non-variant TT) and E5397 treatment arms (cisplatin + placebo versus cisplatin + cetuximab).